Cantargia: New Positive Readout in NSCLC
Research Note
2023-05-26
11:40
Redeye comments on the new readout in non-small cell lung cancer presented at ASCO 2023. In particular, the complete response with nadunolimab as monotherapy is highly encouraging.
RR
Richard Ramanius
Disclosures and disclaimers